Erratum: Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis (Medicine 94:4 (e444) DOI: 10.1097/MD.0000000000000444);Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis

Medicine (United States)

Volumn 94, Issue 4, 2015, Pages E8578-

  Chang, Chia Hao ^a   Lee, Chih Hsin ^b   Ho, Chao Chi ^a   Wang, Jann Yuan ^a   Yu, Chong Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CYCLOSERINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETHAMBUTOL; GEFITINIB; ISONIAZID; KANAMYCIN; PROTEIN TYROSINE KINASE INHIBITOR; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LIVER CIRRHOSIS; LOWEST INCOME GROUP; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMOCONIOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; COHORT ANALYSIS; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; SEX DIFFERENCE; STATISTICAL MODEL; TAIWAN; TUBERCULOSIS, PULMONARY;

CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEX FACTORS; TAIWAN; TUBERCULOSIS, PULMONARY;

EID: 84938088848     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000008578     Document Type: Erratum

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11-30.
2. Lee CK, Brown C, Gralla R.J., et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013; 105:595-605.
3. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009; 10:432-433.
4. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9:154-162.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.
6. Lonnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med. 2008; 29:481-491.
7. Liang HY, Li XL, Yu X.S., et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int J Cancer. 2009; 125:2936-2944.
8. Nechuta S, Lu W, Chen Z., et al. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2011; 20:262-271.
9. Wu CY, Hu HY, Pu C.Y., et al. Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer. 2011; 117:618-624.
10. Yu YH, Liao CC, Hsu W.H., et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011; 6:32-37.
11. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357:539-545.
12. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
13. Bobba RK, Holly JS, Loy T, et al. Scar carcinoma of the lung: a historical perspective. Clin Lung Cancer. 2011; 12:148-154.
14. Nalbandian A, Yan BS, Pichugin A, et al. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene. 2009; 28:1928-1938.
15. Shieh SH, Probst JC, Sung F.C., et al. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. BMC Cancer. 2012; 12:174.
16. Heuvers ME, Aerts JG, Hegmans J.P., et al. History of tuberculosis as an independent prognostic factor for lung cancer survival. Lung Cancer. 2012; 76:452-456.
17. Kuo CH, Lo CY, Chung F.T., et al. Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. PLoS One. 2012; 7:e33226.
18. Luo YH, Wu CH, Wu W.S., et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol. 2012; 7:299-305.
19. Bureau of National Health Insurance. The National Health Insurance Statistics, 2011. http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu-id=296&webdata-id=1942&WD-ID=296. Updated December 14, 2012. Accessed May 10, 2014.
20. Wu JY, Shih JY, Chen K.Y., et al. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine (Baltimore). 2011; 90:159-167.
21. World Health Organization. Global Tuberculosis Control: WHO, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Updated November, 2012. Accessed April 12, 2014.
22. Lokke A, Lange P, Scharling H., et al. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006; 61:935-939.
23. Tabuchi T, Ito Y, Ioka A., et al. Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. Ann Oncol. 2013; 24:2699-2704.
24. Hiscock R, Bauld L, Amos A., et al. Socioeconomic status and smoking: a review. Ann N Y Acad Sci. 2012; 1248:107-123.
25. Methodology WCCfDS. WHO International Working Group for Drug Statistics Methodology: Guidelines for ATC Classification and DDD Assignment Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2011.
26. Lee CH, Lee MC, Lin H.H., et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One. 2012; 7:e37978.
27. Pirkis JE, Speed BR, Yung A.P., et al. Time to initiation of anti-tuberculosis treatment. Tuber Lung Dis. 1996; 77:401-406.
28. Taiwan MotI. Public Assistance Act. Taipei, Taiwan (R.O.C.): Ministry of the Interior; 2010.
29. Lin HH, Ezzati M, Chang H.Y., et al. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med. 2009; 180:475-480.
30. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. J Am Med Assoc. 2005; 294:1505-1510.
31. Marchetti A, Martella C, Felicioni L., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005; 23:857-865.
32. Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010; 11:321-330.
33. Engels EA, Shen M, Chapman R.S., et al. Tuberculosis and subsequent risk of lung cancer in Xuanwei. China Int J Cancer. 2009; 124:1183-1187.
34. Casalino-Matsuda SM, Monzon ME, Forteza RM. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am J Respir Cell Mol Biol. 2006; 34:581-591.
35. Ruano MJ, Hernandez-Hernando S, Jimenez A., et al. Nitric oxide-induced epidermal growth factor-dependent phosphorylations in A431 tumour cells. Eur J Biochem. 2003; 270:1828-1837.
36. Zhang J, Iwanaga K, Choi K.C., et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila). 2008; 1:201-207.
37. Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gend Med. 2010; 7:381-401.
38. Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest. 2005; 128:370-381.
39. North CM, Christiani DC. Women and lung cancer: what is new? Semin Thorac Cardiovasc Surg. 2013; 25:87-94.
40. Kure EH, Ryberg D, Hewer A., et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis. 1996; 17:2201-2205.
41. Calvo A, Catena R, Noble M.S., et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene. 2008; 27:5373-5384.
42. Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS Med. 2009; 6:e1000199.
43. Feng JY, Huang SF, Ting W.Y., et al. Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study. Clin Microbiol Infect. 2012; 18:E331-337.
44. Tsuyuguchi K, Suzuki K, Matsumoto H., et al. Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol. 2001; 123:428-434.
45. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-gamma promoter. J Immunol. 1991; 146:4362-4367.
46. Shang S, Ordway D, Henao-Tamayo M, et al. Cigarette smoke increases susceptibility to tuberculosis-evidence from in vivo and in vitro models. J Infect Dis. 2011; 203:1240-1248.
47. Tachfouti N, Nejjari C, Benjelloun M.C., et al. Association between smoking status, other factors and tuberculosis treatment failure in Morocco. Int J Tuberc Lung Dis. 2011; 15:838-843.
48. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29:2866-2874.
49. Bureau of Health Promotion, Taiwan. Cancer Registry Annual Report, 2010. http://tcr.cph.ntu.edu.tw/uploadimages/CA15-LF100-20140415.pdf. Updated Feb, 2014. Accessed June 10, 2014.
50. Perng RP, Yang CH, Chen Y.M., et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer. 2008; 62:78-84.